FEB 2015 ARTICLE LIST >>
PharmaTutor (February- 2015)
Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 3, Issue 2)
Received On: 24/11/2014; Accepted On: 04/12/2014; Published On: 01/02/2015
AUTHORS: Singh Divya1, Sidhdhi Shrimali2, Rathore KS2*
1Jaipur College of Pharmacy, Jaipur, Rajasthan, India
2BN Institute of Pharmaceutical Sciences, Udaipur, Rajasthan, India
*kamalsrathore@gmail.com
ABSTRACT: Parkinsonism disease (PD) is a progressive neurological disorder. Degeneration of dopamine producing cells in the substantia nigra (part of the basal ganglia) leads to a decreased dopamine production. The cause of the damage is unknown. The main known risk factor is age. Parkinson’s affects functional activities such as balance, walking, speech, handwriting, typing, fastening buttons, driving, and many other simple, or complex but familiar and routine activities, as they are usually controlled by the mechanisms of dopamine and the basal ganglia. This review briefly focuses on deep brain stimulation neurosurgical treatment. Levodopa was the first drug approved specifically for Parkinson’s disease. Levodopa is converted by enzymes in the brain to produce dopamine, thereby supplementing function that has been lost as dopamine-producing neurons die.Topics covered in the review includes pathogenesis, mechanism of action, side effects of medicines and neurological surgery.
How to cite this article: D Singh, S Shrimali, KS Rathore; A Review on Parkinson’s Disease: Its Pathophysiology, Treatment and Surgery; PharmaTutor; 2015; 3(2); 25-32
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and pharmacological management of Parkinson’s disease. A national clinical guideline SIGN; 2010 Jan (SIGN publication no. 113): 1-61.
2. Zigmond MJ, Burke RE. Pathophysiology of Parkinson’s disease. Neuropsychopharmacology: The Fifth Generation of Progress, American College of Neuropsychopharmacology 2002:1781-1793.
3. Houghton D, Hurtig H, Metz S, Brandabur M. Parkinson’s Disease: Medications. National Parkinson Foundation; 2014: 1-72.
4. siberiantimes.com/science/casestudy/news/a-major-breakthrough-in-treating-parkinsons-disease-cannot-reach-patients/ Accessed on Nov. 21, 2014.
5. Aragonans A, Ana BR, Ferguson JC, Jones C, Tugwell C. The Professional’s Guide to Parkinson’s disease. Parkinson’s disease Society of the United Kingdom, 2007; 158 p. Charity registered in England and Wales No. 258197 and in Scotland No. SC037554.
6. wearingoff.eu/what-is-parkinsons/causes-of-parkinsons-disease/ Accessed on Nov. 23, 2014.
7. Tanner CM. Epidemiology of Parkinson’s disease. Neurol Clin 1992; 10:317–329.
8. Langston JW, Ballard PA, Tetrud JW. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219:979–980.
9. Ward CD, Duvoisin RC, and Ince SE, et al. Parkinson’s disease in 65pairs of twins and in a set of quadruplets. Neurology 1983; 33:815–824.
10. Dauer W, Przedborski S. Parkinson’s Disease: Review Mechanisms and Models. Neuron 2003 Sept; 39:889–909.
11. pharmainfo.net/reviews/parkinsons-disease Accessed on Nov. 22, 2014.
12. sharinginhealth.ca/conditions_and_diseases/parkinsons.html Accessed on Nov. 23, 2014.
13. Hardman JG, Limbird LE, Gilman GA. Treatment of central nervous system degenerative disorders. 10th Ed. The pharmacological basis of therapeutics; 2001. Chapter 22; p. 549-560.
14. blogs.brandeis.edu/flyonthewall/translational-findings-how-fruit-flies-are-helping-us-understand-parkinsons-disease/ Accessed on Nov. 22, 2014.
15. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Seminar 2009 June; 373:2055-2066.
16. Hametner E, Seppi K, Poewe W. The clinical spectrum of levodopa-induced motor complications. J Neurol 2010; 257(2):S268-S275.
17. Wood LD, Neumiller JJ, Carlson JD, Setter SM, Corbett CF. Challenges of medication management in hospitalized patients with Parkinson’s disease. Am J Health-Syst Pharm 2010; 67:2059-2063.
18. Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr Dis Treat 2008; 4(4):743-757.
19. Parkinson’s disease Society of the United Kingdom. Drug treatments for Parkinson. A charity registered in England and Wales (258197) and in Scotland (SC037554); 2012 Aug.
20. Robottom BJ. Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson’s disease. Dovepress 2011 Jan; 5:57–64.
21. Brocks DR. Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharmaceut Sci 1999; 2 (2):39-46.
22. michaeljfox.org/mobile/topic.php?medication. Accessed on 16 sept, 2014.
23. Horstink M, Tolosab E, Bonuccellic U, Deuschld G, Friedmane A, Kanovskyf P, Larseng JP, Leesh A, Oerteli W, Poewej W, Rascolk O, Sampaiol C. Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson’s disease. European Journal of Neurology 2006; 13:1170–1185.
24. discoverymedicine.com/Ming-ming-Wen/2012/12/24/advances-and-challenges-in-the-dosage-form-design-for-the-treatment-of-parkinsons-disease/ Accessed on Nov. 22, 2014.
25. azilect.com/AboutParkinsonsDisease/ParkinsonsTreatment. Accessed on Nov. 22, 2014.
26. Tarsy D. Deep Brain Stimulation in Parkinson Disease: Important Information for Patients and Families. Research report, Parkinson report; Winter 2007:8-10.
27. Pahwa R, Lyons KE, Nazzaro M. Deep Brain Stimulation for Parkinson’s disease. Stereotactic and Functional Neurosurgery University of Kansas Medical Center. Accessed on Nov. 11, 2014.
.png)
